Leprosy today

Area of Science:

• Infectious Diseases
• Public Health
• Microbiology

Background:

• Leprosy, caused by Mycobacterium leprae, is prevalent in developing countries, with millions affected globally.
• Transmission occurs mainly through inhalation, and disease presentation varies based on individual immunology.
• Diagnosis relies on characteristic skin lesions, nerve changes, and microscopic identification of bacteria.

Purpose of the Study:

• To outline the current understanding of leprosy, including its epidemiology, diagnosis, and treatment.
• To highlight the effectiveness of multidrug therapy (MDT) in managing leprosy and its complications.
• To discuss the World Health Organization's (WHO) goal of leprosy elimination.

Main Methods:

• Diagnosis involves clinical examination of skin lesions and nerves, alongside Ziehl-Neelsen staining of skin smears for acid-fast bacilli.
• Treatment utilizes multidrug therapy (MDT), a combination of rifampicin, clofazimine, and dapsone for multibacillary leprosy, and rifampicin and dapsone for paucibacillary leprosy.
• Management of complications like reversal reactions and erythema nodosum leprosum primarily involves corticosteroids such as prednisolone.

Main Results:

• Multidrug therapy demonstrates high efficacy in curing leprosy and preventing disease recurrence.
• The duration of MDT, while effective, is still considered lengthy.
• Complications require specific management, often with corticosteroid use.

Conclusions:

• Multidrug therapy is a highly effective treatment for leprosy, leading to successful cures and relapse prevention.
• The success of MDT has supported global initiatives, including the WHO's target to eliminate leprosy as a public health problem.
• Continued efforts and adherence to treatment are crucial for achieving leprosy elimination goals.